PAIN
Volume 132, Issue 1 , Pages 189-194 , November 2007

Validation of the S-LANSS in the community setting

  • Toby N. Weingarten

      Affiliations

    • Division of Pain Medicine, Department of Anesthesia, Mayo Clinic College of Medicine, Rochester, MN, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 507 266 3636.
    • ,
  • James C. Watson

      Affiliations

    • Division of Pain Medicine, Department of Anesthesia, Mayo Clinic College of Medicine, Rochester, MN, USA
    • ,
  • W. Michael Hooten

      Affiliations

    • Division of Pain Medicine, Department of Anesthesia, Mayo Clinic College of Medicine, Rochester, MN, USA
    • ,
  • Peter C. Wollan

      Affiliations

    • Department of Research, Olmsted Medical Center, Rochester, MN, USA
    • ,
  • L. Joseph Melton III

      Affiliations

    • Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, USA
    • ,
  • Adam J. Locketz

      Affiliations

    • Division of Pain Medicine, Department of Anesthesia, Mayo Clinic College of Medicine, Rochester, MN, USA
    • ,
  • Gilbert Y. Wong

      Affiliations

    • Division of Pain Medicine, Department of Anesthesia, Mayo Clinic College of Medicine, Rochester, MN, USA
    • Present address: ALZA Corporation, Clinical Research, Mountain View, CA, USA.
    • ,
  • Barbara P. Yawn

      Affiliations

    • Department of Research, Olmsted Medical Center, Rochester, MN, USA

Received 16 December 2006 ,Revised 31 July 2007 ,Accepted 31 July 2007.

References 

  1. Backonja MM. Need for differential assessment tools of neuropathic pain and the deficits of LANSS pain scale. Pain. 2002;98:229–230
  2. Backonja MM, Krause SJ. Neuropathic pain questionnaire – short form. Clin J Pain. 2003;19:315–316
  3. Bennett M. The LANSS pain scale: the Leeds assessment of neuropathic symptoms and signs. Pain. 2001;92:147–157
  4. Bennett MI, Smith BH, Torrance N, Lee AJ. Can pain can be more or less neuropathic? Comparison of symptom assessment tools with ratings of certainty by clinicians. Pain. 2006;122:289–294
  5. Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. J Pain. 2005;6:149–158
  6. Berger A, Dukes AM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain. 2004;5:143–149
  7. Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E, et al. Development and validation of the neuropathic pain symptom inventory. Pain. 2004;108:248–257
  8. Dyck PJ, Davies JL, Litchy WJ, O’Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology. 1997;49:229–239
  9. Dyck PJ, Turner DW, Davies JL, O’Brien PC, Rask CA. Electronic case-report forms of symptoms and impairments of peripheral neuropathy. Can J Neurol Sci. 2002;29:258–266
  10. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology. 1997;48:332–338
  11. Krause SJ, Backonja MM. Development of a neuropathic pain questionnaire. Clin J Pain. 2003;19:306–314
  12. Melton LJ. History of the Rochester Epidemiology Project. Mayo Clin Proc. 1996;71:266–274
  13. Potter J, Higginson IJ, Scadding JW, Quigley C. Identifying neuropathic pain in patients with head and neck cancer: use of the Leeds assessment of neuropathic symptoms and signs scale. J R Soc Med. 2003;96:379–383
  14. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain. 2006;7:281–289
  15. Watkins E, Wollan PC, Melton LJ, Yawn BP. Silent pain suffers. Mayo Clin Proc. 2006;81:167–171
  16. Yucel A, Senocak M, Kocasoy Orhan E, Cimen A, Ertas M. Results of the Leeds assessment of neuropathic symptoms and signs pain scale in Turkey: a validation study. J Pain. 2004;5:427–432

☆ This work was supported by an unrestricted grant from AstraZeneca.

PII: S0304-3959(07)00434-4

doi: 10.1016/j.pain.2007.07.030

PAIN
Volume 132, Issue 1 , Pages 189-194 , November 2007

Article Tools